Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

CopilotIQ & Biofourmis Merge to Create AI-Driven Platform for In-Home Care

What You Should Know: – CopilotIQ, a health tech company focused on improving the lives of older adults with chronic conditions, and Biofourmis, a global

October 22, 2024

Small Solutions for Big Problems in Drug Discovery and Delivery

Ijeoma Uchegbu discusses nanomedicine’s role in improving medication adherence and developing non-addictive pain relief solutions at ELRIG Drug Discovery 2024.

November 19, 2024

Atantares raises $13.9m in pre-Series A funding to develop molecular chips – Pharmaceutical Technology

DNA synthesis and gene storage are used in drug development and discovery. Credit: Omelchenko / Shutterstock. China-based Atantares has raised approximately 100m yuan ($13.9m) in

August 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.